These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 20217508)

  • 21. Characterization of somatostatin receptors and associated signaling pathways in pancreas of R6/2 transgenic mice.
    Somvanshi RK; Jhajj A; Heer M; Kumar U
    Biochim Biophys Acta Mol Basis Dis; 2018 Feb; 1864(2):359-373. PubMed ID: 29104117
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brain glucose sensing and neural regulation of insulin and glucagon secretion.
    Thorens B
    Diabetes Obes Metab; 2011 Oct; 13 Suppl 1():82-8. PubMed ID: 21824260
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Paracrine control of α-cell glucagon exocytosis is compromised in human type-2 diabetes.
    Omar-Hmeadi M; Lund PE; Gandasi NR; Tengholm A; Barg S
    Nat Commun; 2020 Apr; 11(1):1896. PubMed ID: 32312960
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Automated recognition and quantification of pancreatic islets in Zucker diabetic fatty rats treated with exendin-4.
    Kakimoto T; Kimata H; Iwasaki S; Fukunari A; Utsumi H
    J Endocrinol; 2013 Jan; 216(1):13-20. PubMed ID: 23092878
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Physiology of the pancreatic alpha-cell and glucagon secretion: role in glucose homeostasis and diabetes.
    Quesada I; Tudurí E; Ripoll C; Nadal A
    J Endocrinol; 2008 Oct; 199(1):5-19. PubMed ID: 18669612
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible alpha-cell hyperplasia and hyperglucagonemia.
    Gu W; Yan H; Winters KA; Komorowski R; Vonderfecht S; Atangan L; Sivits G; Hill D; Yang J; Bi V; Shen Y; Hu S; Boone T; Lindberg RA; Véniant MM
    J Pharmacol Exp Ther; 2009 Dec; 331(3):871-81. PubMed ID: 19720878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains.
    Gromada J; Franklin I; Wollheim CB
    Endocr Rev; 2007 Feb; 28(1):84-116. PubMed ID: 17261637
    [TBL] [Abstract][Full Text] [Related]  

  • 28. α-Cells are dispensable in postnatal morphogenesis and maturation of mouse pancreatic islets.
    Shiota C; Prasadan K; Guo P; El-Gohary Y; Wiersch J; Xiao X; Esni F; Gittes GK
    Am J Physiol Endocrinol Metab; 2013 Oct; 305(8):E1030-40. PubMed ID: 23982158
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glucagon antagonism as a potential therapeutic target in type 2 diabetes.
    Bagger JI; Knop FK; Holst JJ; Vilsbøll T
    Diabetes Obes Metab; 2011 Nov; 13(11):965-71. PubMed ID: 21615669
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of dysregulated glucagon secretion in type 2 diabetes.
    D'Alessio D
    Diabetes Obes Metab; 2011 Oct; 13 Suppl 1():126-32. PubMed ID: 21824266
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glucagon is essential for alpha cell transdifferentiation and beta cell neogenesis.
    Ye L; Robertson MA; Hesselson D; Stainier DY; Anderson RM
    Development; 2015 Apr; 142(8):1407-17. PubMed ID: 25852199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Partial ablation of leptin signaling in mouse pancreatic α-cells does not alter either glucose or lipid homeostasis.
    Tudurí E; Denroche HC; Kara JA; Asadi A; Fox JK; Kieffer TJ
    Am J Physiol Endocrinol Metab; 2014 Apr; 306(7):E748-55. PubMed ID: 24473435
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Somatostatin--clinical implications.
    Ciba Found Symp; 1976; 41():313-50. PubMed ID: 780078
    [No Abstract]   [Full Text] [Related]  

  • 34. EphA4 Receptor Forward Signaling Inhibits Glucagon Secretion From α-Cells.
    Hutchens T; Piston DW
    Diabetes; 2015 Nov; 64(11):3839-51. PubMed ID: 26251403
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The physiology of glucagon.
    Taborsky GJ
    J Diabetes Sci Technol; 2010 Nov; 4(6):1338-44. PubMed ID: 21129328
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of glucagon in the pathogenesis of diabetes: the status of the controversy.
    Unger RH
    Metabolism; 1978 Nov; 27(11):1691-709. PubMed ID: 360007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paracrine Interactions within the Pancreatic Islet Determine the Glycemic Set Point.
    Rodriguez-Diaz R; Molano RD; Weitz JR; Abdulreda MH; Berman DM; Leibiger B; Leibiger IB; Kenyon NS; Ricordi C; Pileggi A; Caicedo A; Berggren PO
    Cell Metab; 2018 Mar; 27(3):549-558.e4. PubMed ID: 29514065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glucagon, a key factor in the pathophysiology of type 2 diabetes.
    Girard J
    Biochimie; 2017 Dec; 143():33-36. PubMed ID: 29024725
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in pancreatic somatostatin content in spontaneously diabetic mice, as determined by radioimmunoassay and immunohistochemical methods.
    Makino H; Matsushima Y; Kanatsuka A; Yamamoto M; Kumagai A; Nishimura M
    Endocrinology; 1979 Jan; 104(1):243-7. PubMed ID: 376284
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Insulin as a physiological modulator of glucagon secretion.
    Bansal P; Wang Q
    Am J Physiol Endocrinol Metab; 2008 Oct; 295(4):E751-61. PubMed ID: 18647881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.